The Ozempic Pill: Five Semaglutides, Three Shared Doses

There is now an Ozempic pill, and it is not Rybelsus, and it is not the Wegovy tablet, and all three are semaglutide made by the same company. Three of the tablet strengths appear on two different products with different indications, and the label describes those tablets in identical words. A white round tablet debossed with a 4 is not enough information to know what someone is taking.

Key takeaways#

• Five semaglutide products now exist: Ozempic injection, Ozempic tablets, Rybelsus, Wegovy injection and Wegovy tablets.
• Ozempic tablets are 1.5, 4 and 9 mg. Wegovy tablets are 1.5, 4, 9 and 25 mg. Three strengths are shared, and the label gives both the same physical description.
• In the US, the Ozempic pill replaces Rybelsus (a reformulation renamed in February 2026 and on sale since May 4, 2026), and existing Rybelsus patients move over through their prescriber rather than by a straight swap.
• The label states plainly that Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis, despite being the same molecule from the same maker.
• The diabetes tablets and the weight tablet are different medicines by indication, not different doses of one thing.

The five products, and what each number means#

Everything below is read from the RYBELSUS and OZEMPIC tablets prescribing information and the WEGOVY prescribing information.

Research suggests the reason the numbers look chaotic is that they are answering three different questions at once: how much survives digestion, what the target condition is, and which formulation generation the product belongs to.

The collision worth knowing about#

Ozempic tablets and Wegovy tablets share 1.5 mg, 4 mg and 9 mg.

Label dosing · oral semaglutide

Same tablet strengths, two dose ladders that part at day 61

Both tablets start at 1.5 mg, then 4 mg. From day 61 Ozempic may stay at 4 mg, while Wegovy keeps climbing to 25 mg.

Shared strengths

• 1.5, 4 and 9 mg exist in both products, with the same tablet description

Only Wegovy reaches 25 mg

• A 4 mg tablet is Ozempic maintenance or step two of four on Wegovy

The label describes both products' tablets the same way: white to light yellow, round, debossed with the strength on one side and "novo" on the other. So a 4 mg tablet is either:

• an Ozempic maintenance dose for type 2 diabetes, where 4 mg may be where treatment stays, or
• step two of four on a Wegovy weight ladder heading to 25 mg.

Same molecule, same manufacturer, same tablet face, different medicine. The distinguishing information is on the box and the prescription, not on the tablet.

Ozempic pill replaces Rybelsus, and the swap is not one-for-one#

Studies have shown oral semaglutide works only with an absorption enhancer (SNAC) alongside it, and Rybelsus, approved in 2019, was the first semaglutide tablet. Ozempic tablets are the same molecule in an updated formulation with higher bioavailability, which is why the milligram figures are lower for a comparable effect. Novo Nordisk renamed the reformulation Ozempic tablets in February 2026 and launched it in the US on May 4, 2026; Rybelsus continues to be sold outside the US.

Two consequences follow.

Existing Rybelsus patients do not switch automatically. Novo Nordisk tells them to keep taking Rybelsus as prescribed and to talk with their prescriber about transitioning, because the new tablet has different strengths.

The two are not substitutable on a mg-to-mg basis. That phrase is the label's, not a paraphrase. The mapping it gives instead:

So 7 does not become 7, and someone reading only the milligram figure would conclude their dose had been halved. It has not. The formulation changed underneath it.

The label also says not to switch between them during the initiation phase, only after the first 30 days.

The starting dose that is not meant to work#

Both diabetes tablets open with a step the label describes as not effective for glycemic control: 3 mg for Rybelsus, 1.5 mg for Ozempic tablets, each for 30 days.

Research has shown the escalation exists to blunt gastrointestinal effects rather than to build up an effect, and that is unusual enough to state clearly. It is a tolerability run-in, not an underdose, and a reader who concludes the drug has failed after a month on the first step has misread what the first step is for. The same pattern appears on the Wegovy tablet ladder, where 1.5 mg is an initiation dose on the way to 25.

Switching from the injection#

The label covers this too, and the numbers are again not intuitive.

One week after stopping 0.5 mg Ozempic injection, a patient may start 4 mg or 9 mg Ozempic tablets, or 7 mg or 14 mg Rybelsus. For the weight products, one week after stopping 2.4 mg Wegovy injection, a patient may start 25 mg Wegovy tablets.

The gap between an injected and a swallowed figure is absorption rather than potency, which the Wegovy pill dosage chart works through in detail.

The short version#

One molecule, five products, and three tablet strengths that appear on two of them. Ozempic tablets at 1.5, 4 and 9 mg treat type 2 diabetes. Wegovy tablets at 1.5, 4, 9 and 25 mg treat weight. Rybelsus at 3, 7 and 14 mg is the older oral form being replaced, and its milligram figures do not carry across. Whether Rybelsus helps with weight loss, and why the Wegovy pill is the tablet approved for it, is covered in Rybelsus for weight loss and the Wegovy pill guide.

The number on the tablet is not the whole answer, and the label is unusually explicit about that. For the oral-versus-injection arithmetic, see the Wegovy pill dosage chart. For the injectable ladder in full, see the Wegovy dosage guide. Complete the Klarovel questionnaire to see what the engine recommends from a full health profile.